Dr. James Bristol is a senior advisor on the Frazier Life Sciences team with over 40 years of experience as a chemist and leader of pharmaceutical discovery and research divisions.
Dr. Bristol spent over 30 years in drug discovery research and development at Schering-Plough, Parke-Davis, and Pfizer. He most recently held the position of senior vice president, worldwide discovery research at Pfizer and was responsible for research activities in the United States, United Kingdom and Japan, involving over 3000 scientists at seven research laboratory sites. He has been involved with the discovery and development of many drugs that have been FDA approved or are currently in clinical development, including Lipitor, Lyrica and Ibrance.
Dr. Bristol has also been an adjunct professor of medicinal chemistry at the University of Michigan and editor-in-chief of the American Chemistry Society (ACS) publication series called Annual Reports in Medicinal Chemistry. His research in drug discovery programs – related to the treatment of gastrointestinal, central nervous system and cardiovascular diseases with a focus on mechanistic biochemistry – have been recorded in over 100 publications, abstracts and patents.
In addition to his role at Frazier, Dr. Bristol serves as an independent board member of Ignyta (NASDAQ: RXDX), the chairman of the board of managers of Deciphera Pharmaceuticals, a board member of Mnemosyne Pharmaceuticals and a Karus Pharmaceuticals scientific advisory board member.
Dr. Bristol received a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in chemistry from Bates College. He was an N.I.H. postdoctoral research fellow at the University of Michigan and a postdoctoral fellow at The Squibb Institute for Medical Research.